Antibody-Based Receptor Targeting Using an Fc-Binding Peptide-Dodecaborate Conjugate and Macropinocytosis Induction for Boron Neutron Capture Therapy

Nakase, Ikuhiko; Aoki, Ayako; Sakai, Yuriko Ito; Hirase, Shiori; Ishimura, Miki; Takatani‐Nakase, Tomoka; Hattori, Yoshihide; Kirihata, Mitsunori

doi:10.1021/acsomega.0c01377

Cited by 31 publications

(29 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a method for the highly efficient delivery of boron drugs, investigations using liposomes [ 198 ], antibody modification [ 199 ], and dendrimers [ 200 ] have been reported. Kueffer et al reported that tumor accumulation could be improved by encapsulating BSH in liposomes and improving blood retention, but since BSH also accumulated in normal cells, a strategy to add tumor cell selectivity is necessary [ 201 ] Kang et al reported that BSH was efficiently taken up by cancer cells by encapsulating it in liposomes modified with a peptide that has a high affinity for integrin αvβ3, which is highly expressed in neovascularization and GBM [ 202 ].…”

Section: Relationship Between Boron Neutron Capture Therapy (Bnct) and Boron Compoundsmentioning

confidence: 99%

A Critical Review of Radiation Therapy: From Particle Beam Therapy (Proton, Carbon, and BNCT) to Beyond

Matsumoto

Fukumitsu²,

Ishikawa

et al. 2021

JPM

View full text Add to dashboard Cite

In this paper, we discuss the role of particle therapy—a novel radiation therapy (RT) that has shown rapid progress and widespread use in recent years—in multidisciplinary treatment. Three types of particle therapies are currently used for cancer treatment: proton beam therapy (PBT), carbon-ion beam therapy (CIBT), and boron neutron capture therapy (BNCT). PBT and CIBT have been reported to have excellent therapeutic results owing to the physical characteristics of their Bragg peaks. Variable drug therapies, such as chemotherapy, hormone therapy, and immunotherapy, are combined in various treatment strategies, and treatment effects have been improved. BNCT has a high dose concentration for cancer in terms of nuclear reactions with boron. BNCT is a next-generation RT that can achieve cancer cell-selective therapeutic effects, and its effectiveness strongly depends on the selective 10B accumulation in cancer cells by concomitant boron preparation. Therefore, drug delivery research, including nanoparticles, is highly desirable. In this review, we introduce both clinical and basic aspects of particle beam therapy from the perspective of multidisciplinary treatment, which is expected to expand further in the future.

show abstract

Section: Relationship Between Boron Neutron Capture Therapy (Bnct) and Boron Compoundsmentioning

confidence: 99%

A Critical Review of Radiation Therapy: From Particle Beam Therapy (Proton, Carbon, and BNCT) to Beyond

Matsumoto

Fukumitsu²,

Ishikawa

et al. 2021

JPM

View full text Add to dashboard Cite

show abstract

“…From the TEM‐measured average NP size and the composition assessed by ICP‐MS, it is estimated a number of 10 B atoms for single NP as high as 4.6 10 4 (Figure 2C). This number exceeds by more than three orders of magnitude the 10 B atoms contained in the carborane (B 10 ) derivatives reported in literature as sensitizers for BNCT, such as sodium borocaptate, [ 37,63–68 ] and it is more than four orders of magnitude larger than the 10 B atoms contained in 10 B‐phenylalanine, the most used molecular drug for BNCT. [ 37 ] Noticeably, the density of 10 B atoms per single Fe–B NPs is amenable to a further fivefold increase by performing LAL with a 10 B‐enriched Fe–B metal target.…”

Section: Resultsmentioning

confidence: 99%

Biocompatible Iron–Boron Nanoparticles Designed for Neutron Capture Therapy Guided by Magnetic Resonance Imaging

Torresan

Guadagnini

Badocco

et al. 2020

Adv Healthcare Materials

View full text Add to dashboard Cite

The combination of multiple functions in a single nanoparticle (NP) represents a key advantage of nanomedicine compared to traditional medical approaches. This is well represented by radiotherapy in which the dose of ionizing radiation should be calibrated on sensitizers biodistribution. Ideally, this is possible when the drug acts both as radiation enhancer and imaging contrast agent. Here, an easy, one‐step, laser‐assisted synthetic procedure is used to generate iron–boron (Fe–B) NPs featuring the set of functions required to assist neutron capture therapy (NCT) with magnetic resonance imaging. The Fe–B NPs exceed by three orders of magnitude the payload of boron isotopes contained in clinical sensitizers. The Fe–B NPs have magnetic properties of interest also for magnetophoretic accumulation in tissues and magnetic hyperthermia to assist drug permeation in tissues. Besides, Fe–B NPs are biocompatible and undergo slow degradation in the lysosomal environment that facilitates in vivo clearance through the liver–spleen–kidneys pathway. Overall, the Fe–B NPs represent a new promising tool for future exploitation in magnetic resonance imaging‐guided boron NCT at higher levels of efficacy and tolerability.

show abstract

“…Boron compounds are currently being developed (29)(30)(31)(32)(33)(34)(35). Previous studies showed that tumor uptake after the administration of a sulfhydryl borane dimer (Na 4 B 24 H 22 S 2 ) was approximately two-fold that after the administration of equal amounts of boron as a monomer (36,37) intravenous injection of 10 B-borono-phenylalanine (42).…”

Section: Discussionmentioning

confidence: 99%

Suppression of Tumor Growth in a Rabbit Hepatic Cancer Model by Boron Neutron Capture Therapy With Liposomal Boron Delivery Systems

Yanagië

Yanagawa

Morishita

et al. 2021

In Vivo

View full text Add to dashboard Cite

Background/Aim: Tumor cell destruction by boron neutron capture therapy (BNCT) is attributed to the nuclear reaction between 10 B and thermal neutrons. The accumulation of 10 B atoms in tumor cells without affecting adjacent healthy cells is crucial for effective BNCT. We previously reported that several types of liposomal boron delivery systems (BDS) delivered effective numbers of boron atoms to cancer tissues, and showed tumor-growth suppression after thermal neutron irradiation. In the present study, we examined the effects of BNCT after intra-arterial infusion of 10 B-borono-dodecaborate ( 10 BSH) by liposomal BDS in rabbit hepatic cancer models. Materials and Methods: We prepared 10 BSH-entrapped transferrinconjugated polyethylene glycol liposomes constructed with distearoyl-boron lipid (TF-PEG-DSBL), and performed thermal neutron irradiation at the Kyoto University Institute for Integrated Radiation and Nuclear Science after intraarterial infusion into rabbit VX-2 hepatic tumors. Results: Concentrations of 10 B in VX-2 tumors on delivery with TF-PEG-DSBL liposomes reached 25 ppm on day 3 after the injection. Tumor growth was suppressed by thermal neutron irradiation after intra-arterial injection of this 10 BSHcontaining liposomal BDS, without damage to normal cells. Conclusion: The present results demonstrate the applicability 3125This article is freely accessible online.

show abstract

Antibody-Based Receptor Targeting Using an Fc-Binding Peptide-Dodecaborate Conjugate and Macropinocytosis Induction for Boron Neutron Capture Therapy

Cited by 31 publications

References 26 publications

A Critical Review of Radiation Therapy: From Particle Beam Therapy (Proton, Carbon, and BNCT) to Beyond

A Critical Review of Radiation Therapy: From Particle Beam Therapy (Proton, Carbon, and BNCT) to Beyond

Biocompatible Iron–Boron Nanoparticles Designed for Neutron Capture Therapy Guided by Magnetic Resonance Imaging

Suppression of Tumor Growth in a Rabbit Hepatic Cancer Model by Boron Neutron Capture Therapy With Liposomal Boron Delivery Systems

Contact Info

Product

Resources

About